Friday, July 10, 2026

Drug profile · INN

nirogacestat

nirogacestat (OGSIVEO) is a gamma-secretase inhibitor.

EMA: approved Antineoplastic and immunomodulating agents (L01) L01XX81
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — nirogacestat
Class
Antineoplastic and immunomodulating agents (L01)
Route
Patents
0
Programs
1
Data quality
0.83

Quick answer

nirogacestat (OGSIVEO) is a gamma-secretase inhibitor.

Key facts

INN nirogacestat
Brand OGSIVEO
Mechanism Gamma-secretase inhibitor
Target Gamma-secretase
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XX81

Mechanism of action

Gamma-secretase inhibitor

Primary target: Gamma-secretase

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. 208887 Phase 2 · GSK Glaxo Smith · Multiple Myeloma

Related & competitor drugs

  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is nirogacestat?

nirogacestat (OGSIVEO) is a gamma-secretase inhibitor.

What is the brand name for nirogacestat?

OGSIVEO is a marketed brand name for nirogacestat. Check FDA Drugs@FDA for the current US label holder and prescribing information.